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Background: Sleep restriction therapy (SRT) is a largely untested single treatment component of 
cognitive-behaviour therapy for insomnia. To date, the evidence for contraindications for SRT is 
limited to very few studies. The present study investigated the objective and subjective daytime 
consequences during the acute phase of SRT for adults diagnosed Chronic Insomnia Disorder. 
Methods: Sixteen adults (age=36.3±13.4 yrs, 12 females, 4 males) underwent SRT for their 
insomnia over a 2-week period based on recommendations by Miller and colleagues (2014)
6
. 
Participants completed sleep diaries, self-reported daytime sleepiness (Epworth Sleepiness 
Scale [ESS]), as well as objective measures of reaction time/inhibition (Go/NoGo task) and 
driving performance (AusEd driving simulator) at pre-, mid- (i.e., after 1 week of SRT) and post-
SRT (after 2 weeks of SRT). 
Results: Sleep diary outcomes indicated participants complied with the restriction of time in 
bed, and that a similar amount of total sleep time (TST) was maintained from pre-to-post-
treatment. There was no significant change in daytime sleepiness, and similarly no significant 
changes observed in objective performance on the Go/NoGo task and AusEd driving simulator. 
Conclusions: These preliminary results suggest SRT during the acute phase does not appear to 
place insomnia patients at risk of significant impairments in sleepiness and reaction times. We 
note these findings can only be translated into clinical practice when sleep duration remains 
relatively unchanged. Future studies using objective measures of sleep and a control group are 
recommended. 
 
















An estimated 20% of adults have trouble falling asleep, experience frequent awakenings during 
the night, and feel tired in the morning
1
. Despite this, only 6.9% of the population are 
diagnosed with Chronic Insomnia Disorder
1
. Insomnia is a sleep disorder characterised by the 
difficulty initiating and/or maintaining sleep, even when substantial sleep opportunity is 
available, and is often accompanied by daytime impairments (e.g., excessive daytime 
sleepiness, deficits in attention and concentration)
2,3
.   
  At the present time, there are several well-established pharmacological, behavioural 
and psychological treatments available for insomnia. Cognitive-behavioural therapy for 
insomnia (CBT-I) uses of a combination of behavioural and psychological therapies to improve 
insomnia symptoms (e.g., cognitive therapy, stimulus control therapy) and for many years has 
been considered the gold standard treatment for insomnia
4,5
. One of the arguably most potent 
behavioural therapies within CBT-I is sleep restriction therapy
6
.  
  In a recent meta-analysis, sleep restriction therapy (SRT) was established as an effective 
standalone treatment for insomnia that can achieve sleep improvements in fewer sessions than 
CBT-I
6
. SRT involves providing insomnia patients with a new sleep opportunity window that 
restricts their time in bed to the number of hours they currently spend asleep to avoid spending 
excessive amounts of time in bed (a key maintaining factor of insomnia)
6
. Restricting the 
opportunity for sleep to the average amount of time currently spent asleep (e.g., 12:00 AM to 
6:00 AM if average sleep duration = 6 hrs of sleep per night) increases sleep homeostatic 
pressure across the course of the day/evening, resulting in more consolidated sleep, faster 
sleep onset latency, and increased sleep efficiency (i.e., percentage of time spent asleep whilst 
in bed)
6-8
. These sleep opportunity windows are often altered throughout treatment based on 














of time in bed is afforded, ≤85% SE, 30 min less time in bed). However, an recent consensus 
states that sleep opportunity windows should not be reduced to <5 hrs a night to protect 
against excessive daytime sleepiness
6,9
, since this is often reported as a prominent side effect 
during the acute phase of SRT
3,10,11
. 
 During the acute stage of SRT (i.e., first couple of weeks), many recipients report 
experiencing negative daytime functioning side effects compared to pre-treatment
3
. One study 
that collected audio diary entries and conducted interviews with 18 insomnia participants 
undergoing SRT found that most reported feeling exhausted and irritable, having reduced 
motivation, and experienced difficulty with concentration and memory
3
. However, the study 
did not use any standardised measures of daytime sleepiness (e.g., Epworth Sleepiness Scale 
[ESS]). Of concerning to patients and clinicians is that more than one third of their sample self-
reported compromised driving abilities while undergoing SRT (i.e., difficulty maintaining 
wakefulness, slowed reaction times, concentration impairment)
3
. Despite this, very few studies 
have measured driving performance in people undergoing SRT for insomnia. 
 A later study by Kyle et al. (2014)
11
 administered the ESS to 16 insomnia patients 
receiving SRT and found increased daytime sleepiness in the initial 2 weeks of treatment. This 
daytime sleepiness was reflected in impaired objective performance on a reaction time task
11
. 
Although some studies have used tasks sensitive to attentional lapses such as the psychomotor 
vigilance Task (PVT)
11,12
, there is a lack of literature focusing on inhibitory control and 
concurrent tasking (i.e., halting a pending thought or action to start another) for those 
undergoing SRT, which are arguably important cognitive mechanisms for safe driving
3
.  
 Consequently, the current study sought to determine whether insomnia patients 
undergoing SRT experienced side effects that could impair their functioning (i.e., daytime 














potentially being used worldwide since 1987
9
, to our knowledge there are no data on resultant 
driving performance. Thus, findings from this study will help to inform clinicians providing SRT 
of the potential risks resulting from the therapy, which ethically should be passed onto their 
patients. We anticipate that SRT will result in increased daytime sleepiness during the acute 
phase of treatment (first 2 weeks), as well as slower reaction times and reduced inhibitory 
control (Go/NoGo Task), and poorer driving ability (AusEd Driving Simulator).   
   
Method 
Participants 
16 insomnia participants (mean age = 36.3±13.4 yrs, range 21-58, 12 females, 4 males) 
were recruited through advertisements on Facebook and flyers distributed throughout Flinders 
University and surrounding general practitioner/psychology clinics and community centres. 
Eligible participants met criteria for Chronic Insomnia Disorder based on the International 
Classification of Sleep Disorders, 3
rd
 edition (ICSD-3) criteria
2
. Potential participants were 
excluded if they had a co-morbid sleep disorder associated with excessive daytime sleepiness 
(i.e., narcolepsy or sleep apnoea), had current suicidal ideation, or any other pre-existing 
conditions that could be exacerbated by sleep restriction (i.e., bipolar disorder, epilepsy or 
psychosis)
13-15
, or did not possess a driver’s licence. Ethics approval was granted from the Social 
and Behavioural Research Ethics Committee at Flinders University. 
Materials 
Diagnostic assessment measure 
The diagnostic assessment was in the form of a semi-structured interview based on 
diagnostic criteria based on the ICSD-3
2
, including sleep difficulties (Criterion A), associated 














(Criterion C), frequency (Criterion D) and chronicity (Criterion E) of nighttime/daytime 
symptoms, and differential diagnosis (Criterion F). Other information relevant for 
implementation of SRT was obtained, including napping habits, medications, and caffeine and 
alcohol intake (sleep hygiene).  
Sleep Diary 
Participants were asked to complete a pen-and-paper sleep diary daily, each week, over 
pre-treatment, and 2 weeks of SRT. The sleep diary assisted in confirming the insomnia 
diagnosis and differential diagnosis of other sleep disorders (e.g., circadian rhythm disorders)
16
. 
During treatment, sleep diaries were also used to check participants’ compliance with time in 
bed instructions. The sleep diary provided subjective measures of bedtime, and final rise times, 
time of the sleep attempt, sleep onset latency, wake after sleep onset, time in bed, total sleep 
time, and sleep efficiency. Thus, the sleep diary used in the present study overlapped with the 
core consensus sleep diary
17-18
. Sleep diaries are a valid and reliable method for assessing 




 The Epworth Sleepiness Scale (ESS) is an 8-item questionnaire, used to assess daytime 
sleepiness in a variety of situations over the given day
20
. The ESS was used to screen for 
ineligible participants (ESS scores > 10), track daytime sleepiness, and used as a safety measure 
once treatment had commenced (ESS > 10 afforded an extra 30 min in bed to protect against 
excessive daytime sleepiness). Participants were asked to rate the likelihood of dozing (0 would 
never doze, 3 high chance of dozing) on each item, with higher scores indicative of greater 
levels of sleepiness. The ESS significantly correlates with the multiple sleep latency test, a 

















   
Objective daytime functioning measures  
Reaction Time / Inhibitory Control 
 The Go/NoGo task is a computerised test used as a measure of speed accuracy and 
inhibition
21
. Participants were required to respond to “Go” stimuli (i.e., the letter ‘M’) 
appearing on a computer screen as quickly as possible by tapping the spacebar, yet avoid 
pressing the spacebar when a “No” stimulus was presented (i.e., the letter ‘W’). Each letter was 
displayed for 0.216 sec and the interval between each trial varied between 1300-1700ms, with 
the task lasting 4 min. If participants failed to identify a “Go” stimulus after 500ms, a tone 
sounded, signalling they had missed the stimulus. Reaction times measured their correct 
decision speed, with additional measures of omission accuracy (responses to Go, ‘M’) and 




 The AusEd driving simulator is a computer-based task designed to measure driving 
performance
24
. A standard PC computer was fitted with a steering wheel and 
brake/acceleration apparatus. Steering deviation (in centimetres), speed deviation (in km/h), 
reaction time (ms) and crash frequency (number of crashes) were recorded over a 15-min 
driving simulation. Participants were required to complete a 5-min practice drive to familiarise 
themselves with the simulator before each 15-min drive. Participants were required to drive 
between 60-80km/h and brake completely (i.e., bring car to complete stop) when a truck 
appeared onscreen, and resume driving once the truck disappeared. The task simulates driving 
on a country road at night with features such as engine noise to simulate a real-world driving 
experience. The AusEd driving simulator is sensitive to performance deficits as a result of 


















 Treatment was manualised and based on Spielman et al.’s (1987)
9
 original depiction of 
SRT and a consensus by Miller et al. (2014)
6
. SRT was conducted over a 2-week period at the 
Flinders Insomnia Clinic by clinical, registered and provisional psychologists (mean experience= 
4 yrs 4 mo). The first session involved an assessment to establish study eligibility, followed by 
psychoeducation about SRT (i.e., the premise of sleep homeostatic pressure), and the 
implementation of a new tailored sleep schedule. Sleep schedules were designed in accordance 
with participants’ pre-treatment sleep diaries (i.e., restricting time in bed to equate to their 
average pre-treatment total sleep time), yet prescribed no less than 5 hrs per night (Miller et 
al., 2014)
6
. Immediately after this session (ie, prior to restriction of time in bed), insomnia 
participants’ completed the ESS and were invited to complete computerised testing in order to 
track changes in objective daytime functioning. The computerised tasks were conducted in a 
dimly-lit (<4 lux) sound-attenuated room in the Flinders University Sleep Laboratory, and 
included the Go/NoGo Task and the AusEd driving simulator. 
The following weekly sessions were used to review treatment progress and titrate time 
in bed based on sleep efficiency. Specifically, if sleep efficiency was >85%, or if ESS scores were 
>10, then this afforded the opportunity to extend the amount of time in bed by 30 min (Miller 
et al., 2014)
6
. Following each session, participants once again completed the ESS, Go/NoGo 
Task, and AusEd driving simulator. After the 2 weeks of SRT, insomnia participants were offered 



















Manipulation Check and Sleep Outcomes   
 Linear mixed-model (LMM) regression analyses were performed on time in bed (TIB) to 
establish whether insomnia participants complied with SRT instructions, as well as total sleep 
time (TST) to observe whether sleep had reduced following SRT. LMMs were employed as 
opposed to ANOVAs as the former analytical technique has the ability to model change in 
missing data points (i.e., compensate for missing data)
25
. An AR(1) model was used in LMM’s as 
the study employed a repeated measures time-based model and to also compensate for 
variability in smaller samples
26
.  
 Insomnia participants complied with a reduction in TIB, evidenced by a significant 
decrease in over time F(1,2)=8.52, p=.002. As seen in Table 1, TIB decreased significantly by a 
mean of 1 hr and 10 min from pre- to mid-treatment, and 1 hr and 23 min from pre- to post-
treatment. However, despite a mean TST decrease of 32 min from pre- to post-treatment, TST 
did not significantly change during SRT, F(1,2)=2.56, p =.10. Sleep onset latency significantly 
reduced from pre-treatment (51 min) to post-treatment (23 min), F(1,2)=7.56, p=.004, as did 
wake after sleep onset (WASO; pre-treatment=75 min to post- treatment=38 min), F(1,2)=5.67, 
p=012. However, there was no significant change in sleep efficiency, F(1,2)=1.33, p=.29. 
 
< Insert Table 1 about here > 
 
Daytime functioning outcomes 
No significant changes in ESS scores occurred during the study, F(1,2) = 0.84, p=.45, 














changes in reaction times, F(1,2)=2.75,p=.09, commission accuracy F(1,2)=0.25, p=.78, or 
omission accuracy F(1,2)=0.33, p=.72 on the GONOGO reaction time/inhibitory task. Likewise, 
there were no significant changes to various domains of driving ability, including reaction times, 
F(1,2)=0.60, p=.56, speed deviation, F(1,2)=0.58, p=.57, steering deviation, F(1,2)=1.82, p=.19, 
or crash frequency, F(1,2)=0.00, p=.99, on the AusEd driving simulator.  
  
< Insert Table 2 about here > 
 
Discussion 
The aim of the current study was to investigate subjective and objective changes in daytime 
functioning and performance during the acute phase (first 2 weeks) of sleep restriction therapy 
(SRT). Despite insomnia participants’ compliance with SRT, no significant changes were 
observed in reaction times, inhibition, driving performance variables or daytime sleepiness 
during the acute phase of treatment. These findings suggest SRT for the treatment of insomnia 
does not appear to negatively impact driving performance or other aspects of daytime 
functioning that would place patients at risk regarding their safety.  
Insomnia participants adhered to the SRT protocol (as per Miller et al., 2014)
6
 as 
evidenced by a significant 81-min reduction in TIB (from 8 hrs 41 min to 7 hrs 20 min).  From 
week 1 to week 2 of SRT there was no significant change in TIB indicating similar sleep 
schedules were maintained across the treatment period. Despite this significant reduction in 
TIB, there was no significant change in TST across treatment. We do note though a mean 
decrease of 32 min in TST, which may be a meaningful reduction of sleep duration from pre-
treatment. Therefore, we now discuss the outcomes from the perspective of this mild sleep 














 We anticipated that self-reported daytime sleepiness (ESS scores) would increase from 
pre-treatment to post-treatment (i.e., the acute 2 weeks of SRT). However, this was not 
observed. This prediction was based on the premise that insomnia patients may have 
experienced reductions in TST, as well as results from previous studies
11
. The lack of change in 
our participants’ self-reported daytime sleepiness, even in response to a mean 32-min 
reduction in TST, aligns with previous studies of stable daytime sleepiness after 1 week of ~30-
min less TST in good sleepers
27





 over an approximately 2-week period produce increases in daytime 
sleepiness. Taken together, the findings suggest that a reduction of ~30-min of TST during the 
acute phase of SRT (ie, first 2 weeks) is not potent enough to result in changes in patients’ 
perceived daytime sleepiness. If anything, we note no change after 1 week of SRT (d=0.02), yet 
a small decrease (d=0.44) from mid-treatment (i.e., after 1 week of SRT) to post-treatment (i.e., 
after 2 weeks of SRT), suggesting a reduced risk for insomnia patients undergoing SRT. 
However, an important contribution from the present study is systemically examining multiple 
outcome measures, so as not to rely solely on patients’ ESS scores. 
The Go/NoGo task was an objective test of participants’ reaction times and inhibition
21
. 
Although previous studies found increased reaction times (using the PVT) following sleep 
restriction in good sleepers
12,29
 and from SRT for insomnia
11
, the present study did not find such 
deficits. Even in the context of a 32-min TST reduction, effect sizes during SRT were virtually nil 
(ds=0.00-0.03). Similarly, both omission and commission accuracy did not significantly change, 
with negligible effects for omission accuracy (i.e., accidently responding to ‘NoGo’ stimulus; 
ds=0.06-0.10). Although small effects were found for omission accuracy (i.e., correctly 
responding to ‘Go’ stimulus; ds=0.23-0.27), the actual percentage change was within 1% which 














Driving performance was the second objective task used during the acute phase of SRT, 
as insomnia patients undergoing SRT self-report driving difficulties
3 
yet to our knowledge this 
has not been objectively verified. Contrary to expectations, reaction time, speed deviation, 
steering deviation and crash frequency did not deteriorate over the treatment period. Although 
small effects occurred during SRT (i.e., Δreaction time=0.06ms; Δsteering deviation=4cm; 
Δspeed deviation<0.2km/hr), these are not meaningful. Previous studies using the AusEd 
driving simulator have reported deficits in driving parameters, however these were observed 
following a significant reduction in total sleep time and/or consumption of alcohol in good 
sleepers (e.g., TIB=5 hrs)
30,31
. Given insomnia patients’ self-reports of impaired driving whilst 
undergoing SRT, more data are required to more confidently claim that it is safe for such 
patients to drive during the acute phases of treatment.   
Implications 
The present study provides preliminary evidence to suggest SRT may be a safe clinical 
intervention for people with insomnia. The chances of dozing, reaction times, inhibitory control 
and driving performance remained relatively stable after 2 weeks of SRT. This appears to occur 
despite a reduction of ~30-min (or less) sleep duration. Insomnia patients’ self-reports of 
driving performance may not mirror objective assessments of driving performance, which 
supports theoretical models of distorted daytime performance deficits
32
. However at this stage, 
we reserve the use of these preliminary findings to psychoeducation (over behavioural 
experiments) during treatment. Although we did not objectively measure TST during SRT like 
previous studies
11
, the use of polysomnography or wrist actigraphy is arguably not the norm in 
clinical practice, whereas sleep diaries are more accessible. This suggests the findings from the 
present study are applicable broadly to clinicians performing SRT. Likewise, while our sample 














alone treatment for insomnia (N=16-18)
3,11
, and it included a range of mental health and 





Limitations and Future Directions 
Research to answer the question “Is sleep restriction therapy safe?” would be enhanced 
by further replication, using sample sizes larger than that in the present study (N=16) and 
others (N=16-18)
3,11
, and including a control group (e.g., waitlist control). We do not necessarily 
suggest larger samples to be tested in order to detect statistical significance (as we believe the 
meaningfulness of changes is important), but more so that findings can be generalised better to 
insomnia patients undergoing SRT. It is not exactly known how much sleep patients obtained 
during the present study, as no objective measures were used
11,36-37
. Therefore, future studies 
are recommended to use both subjective (sleep diary) and objective (wrist actigraphy) 
measures of sleep quantity during SRT. Simultaneous measurement would also address the 
issue that a significant proportion of people with insomnia experience sleep misperception (i.e., 
under-estimate TST)
38
, which could lead to more accurate implementation of SRT. We also note 
that the present study used a 15-min driving simulator, so future studies should consider 
extending the duration (e.g., 60 min)
24
. This will give an indication as to whether or not 
sustained attention whilst driving deteriorates, or whether it remains the same over a longer 
period of time.  
Conclusions  
Despite sleep restriction therapy (SRT) being available for clinicians and insomnia 
patients since 1987
9
, it is surprising that after 30 years that there are very few data directly 














adhering to recent guidelines (Miller et al., 2014)
6
, SRT does not appear to negatively impact 
daytime functioning and driving performance. This lack of effect assumes a nil-to-mild 
reduction of total sleep time during treatment (i.e., less than 30 min). However, future 
investigations of SRT as a stand-alone treatment are needed, with preferably a larger sample 
size and control group in order to make clearer judgements for people with Chronic Insomnia 
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Table 1. Changes in sleep outcomes from pre- to mid- to post-treatment.  
 
 Time 
 Pre   Mid   Post   
 M CI  M CI  M CI  
Sleep outcomes          
TIB (hrs) 8.68 7.97-9.39  7.43 6.72-8.14  7.33 6.57-8.1  
TST (hrs) 6.30 5.55-7.05  5.83 5.08-6.58  5.77 5.00-6.55  
WASO (mins) 75.58 51.69-99.48  38.52 14.62-62.42  38.4 11.08-65.72  
SOL (mins) 51.09 37.36-64.82  26.1 12.37-39.83  23.86 37.36-64.82  
SE (%) 73.19 65.55-80.84  79.01 70.68-87.35  79.21 71.57-86.86  
          
 
Note: Pre= pre-treatment; Mid = after 1 week of SRT; Post = after 2 weeks of SRT. TIB = time in bed; TST = total 
sleep time; WASO = wake after sleep onset; SOL = sleep onset latency; SE = sleep efficiency; M = estimated 



















Note: Pre= pre-treatment; Mid = after 1 week of SRT; Post = after 2 weeks of SRT. ESS= Epworth Sleepiness Scale. Cohen’s d effect size 
magnitude: .20 = small, .50 = moderate, .80 = large. CI = 95% confidence interval.  
 
 
 Pre  Pre-mid Mid  Pre-post Post  
 M CI d M CI d M CI 
ESS         
Sleepiness  7.00 4.28-9.72 0.02 7.12 3.34-10.95 0.41 4.46 0.54-8.37 
GO/NOGO         
Reaction times (ms) 0.34 0.31-0.36 0.00 0.33 0.31-0.35 0.03 0.35 0.35-0.37 
Commission 
accuracy (%) 
75.51 64.79-86.23 0.10 77.65 66.2-89.10 0.06 74.46 63.88-85.05 
Omission accuracy 
(%) 






AusEd         
Reaction time (ms) 0.97 0.85-1.08 0.09 0.95 0.83-1.06 0.36 0.89 0.76-1.02 
Steering deviation 
(cm) 
30.87 23.10-38.63 0.30 35.19 27.43-42.95 0.29 35.12 26.97-43.28 
Speed deviation 
(km/h) 
0.85 0.42-1.28 0.21 0.68 0.25-1.11 0.11 0.76 0.28-1.23 















• Sleep restriction therapy (SRT) is an effective treatment component of cognitive-
behaviour therapy for insomnia 
 
• Restriction of sleep can induce excessive daytime sleepiness and reaction times. 
 
• Applying SRT as per recent guidelines led to a mean decrease in sleep duration of 32 
minutes. 
 
• No significant changes in sleepiness, reaction times or driving performance were 
found whilst insomnia patients underwent 2 weeks of SRT. 
